top of page

PersisT Study

This study aims to characterize apheresis products of commercial CAR patients in efforts to unmask biologic predictors of CAR persistence.

ADDITIONAL ELIGIBILITY

  1. Pediatric and young adults with ALL who have previously undergone standard of care therapy with FDA approved immunotherapy, such as: Kymriah™ (CTL019, tisagenlecleucel)

COLLECTION

previously banked (pre-manufactured) apheresis product samples

  • vials preferred; if bags, thaw and aliquot into 2ml cryovials

REQUIREMENTS

Institutional biobanking ICF that allows for future research on banked samples OR Foresight ICF signed

bottom of page